Caricamento...
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
BACKGROUND: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the e...
Salvato in:
| Pubblicato in: | J Gastrointest Oncol |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776800/ https://ncbi.nlm.nih.gov/pubmed/31602329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.06.02 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|